Similar articles

• Study of thymic factors. II. Failure of thymosin to alter the natural history of NZB and NZB/NZW mice.

  Gershwin ME, Steinberg AD, Ahmed A, Derkay C. Gershwin ME, et al. Arthritis Rheum. 1976 Sep-Oct;19(5):862-6. doi: 10.1002/art.1780190505. Arthritis Rheum. 1976. PMID: 1085626
• The endocrine thymus: potential role for thymosin in the treatment of autoimmune disease.

  Goldstein AL, Thurman GB, Cohen GH, Rossio JL. Goldstein AL, et al. Ann N Y Acad Sci. 1976;274:390-401. doi: 10.1111/j.1749-6632.1976.tb47700.x. Ann N Y Acad Sci. 1976. PMID: 786112 Review. No abstract available.
• Thymosin administration in autoimmune disorders.

  Lavastida MT, Goldstein AL, Daniels JC. Lavastida MT, et al. Thymus. 1981 Feb;2(4-5):287-95. Thymus. 1981. PMID: 6972106
• [Clinical effectiveness of the treatment of systemic lupus erythematosus with preparations of the methylxanthine group and T-activin].

  Biriukov AV, Stenina MA, Anan'eva LP, Skripnik AIu, Cheredeev AN. Biriukov AV, et al. Klin Med (Mosk). 1987 Jan;65(1):107-11. Klin Med (Mosk). 1987. PMID: 3550275 Clinical Trial. Russian. No abstract available.
• [Immunostimulant therapy of kidney diseases].

  Karastanev I. Karastanev I. Vutr Boles. 1982;21(3):8-13. Vutr Boles. 1982. PMID: 6180558 Review. Bulgarian. No abstract available.